Psychedelic Medicine

Association

Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review

Excerpts from the publication

Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD), psilocybin and dimethyltryptamine (DMT). Some studies suggest that these substances might be effective in depression treatment. The aim of this study was to evaluate the efficiency of LSD, psilocybin and DMT in depression treatment in the light of current medical literature. The authors followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines for this systematic review. The authors searched the PubMed and Cochrane Library databases to identify relevant publications. Finally, 10 papers were included. Most of the selected studies showed significant correlation between psilocybin and DMT use and reduction in depression symptom intensity. By analyzing qualified studies, it can be concluded that psilocybin and DMT could be useful in depression treatment, but further observations are still required

Read more

Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample

Ketamine in fibromyalgia: a systematic review

Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): a stressor on the immune system

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions

Expectancy in placebo-controlled trials of psychedelics: if so, so what?